Clinical trial
A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes
NCT00324194 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes
- Lead sponsor
- Mirati Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2005
- Completion date
- August 31, 2008
- Enrollment
- 25 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.